BCL6 and B-cell non-Hodgkin lymphoma: Furthermore, BCL6 inhibitors are currently in clinical trials for treatment of B-cell Non-Hodgkin’s Lymphoma, streamlining the process for regulatory approval as a new potential T1D immunotherapy 55.